Rivaroxaban in Chronic Hemodialysis Patients
نویسندگان
چکیده
منابع مشابه
Rivaroxaban in Chronic Hemodialysis Patients: Clarification of an Editorial Error.
J.A. is a full-time employee of Janssen Research & Development, LLC. C.D., K.T.M., J.M. and R.M.M. were full-time employees of Janssen Research & DevelopThe recently published Editorial by Muster and Alcorn [1] contains an inaccuracy related to the incidence of thrombosis reported in our manuscript entitled, ‘Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Rivaroxaban in Chronic H...
متن کاملDabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.
BACKGROUND Dabigatran and rivaroxaban are new oral anticoagulants that are eliminated through the kidneys. Their use in dialysis patients is discouraged because these drugs can bioaccumulate to precipitate inadvertent bleeding. We wanted to determine whether prescription of dabigatran or rivaroxaban was occurring in the dialysis population and whether these practices were safe. METHODS AND RE...
متن کاملDialysis adequacy of chronic hemodialysis patients in Zanjan-Iran, 2016
Background: Dialysis adequacy is one of the most important factors in determining the survival rate and mortality of dialysis patients. Objectives: The aim of this study was to determine the dialysis adequacy of patients undergoing chronic hemodialysis at dialysis centers located in the province of Zanjan, located in northwest Iran. Methods: This descriptive cross-sectional study was performe...
متن کاملAntitetanus Toxoid Antibody Titer of Chronic Hemodialysis Patients in Iran
Background: Patients with end stage renal disease have higher incidence of infection dis-eases that is thought to be related to impaired immune system. Objective: To determine the antitetanus IgG antibody level in Iranian hemodialysis patients with end stage renal disease and to find its association with sex, age, blood hemoglobin, serum albumin, dura-tion of dialysis, time of dialysis per week...
متن کاملPharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Rivaroxaban in Chronic Hemodialysis.
BACKGROUND This study aimed to characterize the single-dose pharmacokinetic (PK) and pharmacodynamic (PD) profile of rivaroxaban 15 mg administered before and after dialysis in subjects with end-stage renal disease (ESRD), and to compare this profile in subjects with ESRD to that in healthy control subjects (creatinine clearance ≥80 ml/min). METHODS This was an open-label, single-dose, single...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: American Journal of Nephrology
سال: 2016
ISSN: 0250-8095,1421-9670
DOI: 10.1159/000445329